Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Summary

The women’s health market represents a small but growing therapy area. There are currently 277 pipeline products in active development for women’s health, making it the 16th largest therapy area by pipeline size. Key indications within the area include endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia, menopausal disorders and infertility.

The global market is projected to grow at a compound annual growth rate (CAGR) of 5.16% till 2024. This relatively strong growth will be driven by a number of factors. These include the strong growth projected for human papillomavirus (HPV) vaccines, which are administered to girls and women in order to prevent development of CIN, an abnormality of the cells on the surface of the cervix, which can progress to cervical cancer in some cases.

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

Some 246 licensing deals have been completed within the women’s health therapy area since 2006, demonstrating a relatively high level of activity, considering the small size of the therapy area. Co-development deal activity has been much lower, with only 78 deals completed since 2006.

The strategic consolidations landscape was largely dominated by small molecule products and products acting on G-protein coupled receptors (GPCR). The majority of deals identified were relatively low value although a small number of deals exceeded $500m in value, demonstrating that women’s health products are capable of attracting high levels of investment.

The report Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

Scope

• There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
• Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
• Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
• The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
• In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

• Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
• Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
• Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
• Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
• Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.